The XeriSol™ formulation technology platform is specifically designed to produce optimal stability and solubility with peptide-based drugs through proprietary formulation in biocompatible, non-aqueous solvents. The XeriSol platform can achieve high solubility and room temperature stability for peptide drugs currently encountering formulation challenges. Xeris’s platforms have the potential to offer distinct advantages over existing formulations of marketed and development-stage drugs and biologics. In particular, XeriSol™ offers the opportunity to:
• Eliminate reconstitution
• Enable long-term room-temperature stability
• Significantly reduce injection volume
• Eliminate the requirement for IV infusion – convert to subcutaneous injection or infusion drugs that previously required large-volume IV administration
• Enable co-delivery/co-formulation of active pharmaceutical ingredients
We have a strong global patent position for both XeriSol™ providing patent protection out to 2036.
Dr. Steve Prestrelski is the Founder and Chief Scientific Officer of Xeris Pharmaceuticals, Inc., a company focused on creating enhanced injectable formulations based on proprietary non-aqueous formulation platforms. He has worked in the biopharmaceutical and drug delivery industries for >25 years with companies such as Amgen, Alza, PowderJect and Amylin. Steve has an BS degree in Nutrition Science from Drexel University, a PhD in biophysics from City University of New York and an MBA from the Rady School of Management at UC San Diego.